Fig. 8: Clinical implications of RBM15 target genes and clinical efficacy of RBM15 in BC patients. | Experimental & Molecular Medicine

Fig. 8: Clinical implications of RBM15 target genes and clinical efficacy of RBM15 in BC patients.

From: The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism

Fig. 8

a Molecular subtypes of PHGDH, PSAT1, PSPH, and SHMT2 in the TCGA-BRCA cohort. b Correlations between RBM15 and PHGDH, PSAT1, PSPH, and SHMT2 gene expression in the indicated TCGA-BRCA cohort. Scatter plots of RBM15 and related genes in the cohorts are shown for the indicated cohorts. c, d Kaplan‒Meier plots of OS outcomes in patients from the TCGA-BRCA cohort. e ROC curve analysis was performed to assess the correlation of RBM15 gene expression levels with chemotherapy response by determining the area under the curve (AUC), which was estimated through the concordance index. The corresponding p values were determined using one-sided Wilcoxon’s signed-rank test. f–h After MDA-MB-231 cells were injected into nude mice, the indicated siRNAs containing CH-NPs were administered according to the indicated treatment schedule (f). A representative image of a tumor is shown. g The tumor volumes were measured (h). i Schematic diagram of the RBM15 gene regulatory mechanism. All results are expressed as the means ± standard deviations of three independent replicates (*p < 0.05 and **p < 0.01).

Back to article page